(NASDAQ: EYPT) Eyepoint Pharmaceuticals's forecast annual revenue growth rate of 11.99% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Eyepoint Pharmaceuticals's revenue in 2025 is $42,340,000.On average, 15 Wall Street analysts forecast EYPT's revenue for 2025 to be $2,685,782,991, with the lowest EYPT revenue forecast at $2,498,849,448, and the highest EYPT revenue forecast at $3,111,971,600. On average, 15 Wall Street analysts forecast EYPT's revenue for 2026 to be $902,546,272, with the lowest EYPT revenue forecast at $0, and the highest EYPT revenue forecast at $3,911,696,145.
In 2027, EYPT is forecast to generate $6,374,450,366 in revenue, with the lowest revenue forecast at $389,431,083 and the highest revenue forecast at $16,429,123,809.